<DOC>
	<DOC>NCT02959970</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.</brief_summary>
	<brief_title>Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions (noninflammatory and/or inflammatory). Has uncontrolled systemic disease(s) Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, druginduced acne) Has used topical dapsone within 1 month prior to the screening Has used oral dapsone within 2 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>